Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, signaling a version update to the study record page rather than a substantive content change.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check30 days agoChange DetectedThe page revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check52 days agoChange DetectedThe study EV-103 (NCT03288545) was terminated by the sponsor after meeting enrollment targets and primary objectives, with data collected for planned regulatory filings. The page updates recruitment status to reflect termination, including removal of the 'Active, not recruiting' designation and related dates.SummaryDifference0.2%

- Check59 days agoChange DetectedAdded revision: v3.5.0. Removed revision: v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.